Is PIPAC a Treatment Option in Upper and Lower Gastrointestinal Cancer with Peritoneal Metastasis?

2.

Thomassen

I

,

van Gestel

YR

,

van Ramshorst

B

,

Luyer

MD

,

Bosscha

K

,

Nienhuijs

SW

,

Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors

.

Int J Cancer

.

2014

;

134

(

3

):

622

–

8

.

https://doi.org/10.1001/jama.2017.21421

3.

Henderson

JT

,

Webber

EM

,

Sawaya

GF

.

Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force

.

JAMA

.

2018

;

319

(

6

):

595

–

606

.

.

4.

Franko

J

,

Shi

Q

,

Meyers

JP

,

Maughan

TS

,

Adams

RA

,

Seymour

MT

,

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

.

Lancet Oncol

.

2016

;

17

(

12

):

1709

–

19

.

https://doi.org/10.1016/j.soc.2018.02.006

5.

Dahdaleh

FS

,

Turaga

KK

.

Evolving treatment strategies and outcomes in advanced gastric cancer with peritoneal metastasis

.

Surg Oncol Clin N Am

.

2018

;

27

(

3

):

519

–

37

.

.

https://doi.org/10.1097/01.sla.0000197382.43208.a5

6.

Sarela

AI

,

Miner

TJ

,

Karpeh

MS

,

Coit

DG

,

Jaques

DP

,

Brennan

MF

.

Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma

.

Ann Surg

.

2006

;

243

(

2

):

189

–

95

.

.

7.

Lorenzen

S

,

Panzram

B

,

Rosenberg

R

,

Nekarda

H

,

Becker

K

,

Schenk

U

,

Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection

.

Ann Surg Oncol

.

2010

;

17

(

10

):

2733

–

9

.

8.

Fuchs

CS

,

Muro

K

,

Tomasek

J

,

Van Cutsem

E

,

Cho

JY

,

Oh

SC

,

Prognostic factor analysis of overall survival in gastric cancer from two phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data

.

J Gastric Cancer

.

2017

;

17

(

2

):

132

–

44

.

https://doi.org/10.1002/bjs.4473

9.

Glehen

O

,

Cotte

E

,

Schreiber

V

,

Sayag-Beaujard

AC

,

Vignal

J

,

Gilly

FN

.

Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin

.

Br J Surg

.

2004

;

91

(

6

):

747

–

54

.

.

https://doi.org/10.1016/s1470-2045(03)01074-x

10.

Markman

M

.

Intraperitoneal antineoplastic drug delivery: rationale and results

.

Lancet Oncol

.

2003

;

4

(

5

):

277

–

83

.

.

11.

Solass

W

,

Herbette

A

,

Schwarz

T

,

Hetzel

A

,

Sun

JS

,

Dutreix

M

,

Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept

.

Surg Endosc

.

2012

;

26

(

3

):

847

–

52

.

https://doi.org/10.1007/s10354-014-0312-y

12.

Tempfer

CB

,

Solass

W

,

Reymond

MA

.

Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review

.

Wien Med Wochenschr

.

2014

;

164

(

23–24

):

519

–

28

.

.

13.

Bakrin

N

,

Tempfer

C

,

Scambia

G

,

De Simone

M

,

Gabriel

B

,

Grischke

EM

,

PIPAC-OV3: a multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as pressurized intra-peritoneal aerosol chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

.

Pleura Peritoneum

.

2018

;

3

(

3

):

20180114

.

14.

Nowacki

M

,

Alyami

M

,

Villeneuve

L

,

Mercier

F

,

Hubner

M

,

Willaert

W

,

Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study

.

Eur J Surg Oncol

.

2018

;

44

(

7

):

991

–

6

.

15.

Facy

O

,

Al Samman

S

,

Magnin

G

,

Ghiringhelli

F

,

Ladoire

S

,

Chauffert

B

,

High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study

.

Ann Surg

.

2012

;

256

(

6

):

1084

–

8

.

https://doi.org/10.1016/j.soc.2018.02.003

16.

Lagast

N

,

Carlier

C

,

Ceelen

WP

.

Pharmacokinetics and tissue transport of intraperitoneal chemotherapy

.

Surg Oncol Clin N Am

.

2018

;

27

(

3

):

477

–

94

.

.

17.

Khosrawipour

V

,

Khosrawipour

T

,

Kern

AJ

,

Osma

A

,

Kabakci

B

,

Diaz-Carballo

D

,

Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model

.

J Cancer Res Clin Oncol

.

2016

;

142

(

11

):

2275

–

80

.

18.

Smyth

EC

,

Verheij

M

,

Allum

W

,

Cunningham

D

,

Cervantes

A

,

Arnold

D

,

Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

.

Ann Oncol

.

2016

;

27

(

Suppl 5

):

v38

–

49

.

19.

Van Cutsem

E

,

Cervantes

A

,

Adam

R

,

Sobrero

A

,

Van Krieken

JH

,

Aderka

D

,

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

.

Ann Oncol

.

2016

;

27

(

8

):

1386

–

422

.

20.

Verwaal

VJ

,

van Ruth

S

,

de Bree

E

,

van Sloothen

GW

,

van Tinteren

H

,

Boot

H

,

Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer

.

J Clin Oncol

.

2003

;

21

(

20

):

3737

–

43

.

21.

Quenet

F

,

Elias

D

,

Roca

L

,

Goere

D

,

Ghouti

L

,

Pocard

M

,

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial

.

Lancet Oncol

.

2021

;

22

(

2

):

256

–

66

.

22.

Oliver Goetze

T

,

Al-Batran

SE

,

Pabst

U

,

Reymond

M

,

Tempfer

C

,

Bechstein

WO

,

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naive upper gi-adenocarcinomas with peritoneal seeding: a phase II/III trial of the AIO/CAOGI/ACO

.

Pleura Peritoneum

.

2018

;

3

(

2

):

20180113

.

23.

Alyami

M

,

Hubner

M

,

Grass

F

,

Bakrin

N

,

Villeneuve

L

,

Laplace

N

,

Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications

.

Lancet Oncol

.

2019

;

20

(

7

):

e368

–

77

.

https://doi.org/10.1186/s12957-016-0892-7

24.

Robella

M

,

Vaira

M

,

De Simone

M

.

Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis

.

World J Surg Oncol

.

2016

;

14

:

128

.

.

https://doi.org/10.1245/s10434-012-2840-2

25.

Blanco

A

,

Giger-Pabst

U

,

Solass

W

,

Zieren

J

,

Reymond

MA

.

Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC)

.

Ann Surg Oncol

.

2013

;

20

(

7

):

2311

–

6

.

.

https://doi.org/10.7150/jca.21460

26.

Teixeira Farinha

H

,

Grass

F

,

Labgaa

I

,

Pache

B

,

Demartines

N

,

Hübner

M

.

Inflammatory response and toxicity after pressurized intraperitoneal aerosol chemotherapy

.

J Cancer

.

2018

;

9

(

1

):

13

–

20

.

.

27.

Hubner

M

,

Teixeira Farinha

H

,

Grass

F

,

Wolfer

A

,

Mathevet

P

,

Hahnloser

D

,

Feasibility and safety of pressurized intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort Study

.

Gastroenterol Res Pract

.

2017

;

2017

:

6852749

.

28.

Kurtz

F

,

Struller

F

,

Horvath

P

,

Solass

W

,

Bosmuller

H

,

Konigsrainer

A

,

Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study

.

Gastroenterol Res Pract

.

2018

;

2018

:

2743985

.

29.

Siebert

M

,

Alyami

M

,

Mercier

F

,

Gallice

C

,

Villeneuve

L

,

Berard

F

,

Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report

.

Cancer Chemother Pharmacol

.

2019

;

83

(

3

):

425

–

30

.

30.

Shitara

K

,

Muro

K

,

Shimada

Y

,

Hironaka

S

,

Sugimoto

N

,

Komatsu

Y

,

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

.

Gastric Cancer

.

2016

;

19

(

3

):

927

–

38

.

31.

Siebert

M

,

Alyami

M

,

Mercier

F

,

Gallice

C

,

Villeneuve

L

,

Laplace

N

,

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study

.

Eur J Surg Oncol

.

2021

;

47

(

1

):

139

–

42

.

32.

Feldbrugge

L

,

Gronau

F

,

Brandl

A

,

Auer

TA

,

Oeff

A

,

Thuss-Patience

P

,

Systemic chemotherapy including ramucirumab in combination with pressurized intra-peritoneal aerosol chemotherapy is a safe treatment option for peritoneal metastasis of gastric cancer

.

Front Oncol

.

2020

;

10

:

610572

.

33.

Gockel

I

,

Jansen-Winkeln

B

,

Haase

L

,

Rhode

P

,

Mehdorn

M

,

Niebisch

S

,

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal metastasis (PM): results of a single-center experience and register study

.

J Gastric Cancer

.

2018

;

18

(

4

):

379

–

91

.

34.

Demtroder

C

,

Solass

W

,

Zieren

J

,

Strumberg

D

,

Giger-Pabst

U

,

Reymond

MA

.

Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis

.

Colorectal Dis

.

2016

;

18

(

4

):

364

–

71

.

35.

Teixeira Farinha

H

,

Grass

F

,

Kefleyesus

A

,

Achtari

C

,

Romain

B

,

Montemurro

M

,

Impact of pressurized intraperitoneal aerosol chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a retrospective cohort study

.

Gastroenterol Res Pract

.

2017

;

2017

:

4596176

.

36.

Reid

JL

,

Kanhere

HA

,

Hewett

PJ

,

Price

TJ

,

Maddern

GJ

,

Trochsler

MI

.

Can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O+) be added to standard treatment for resectable high-risk gastric cancer patients? A study protocol

.

Pleura Peritoneum

.

2021

;

6

(

4

):

151

–

4

.

37.

Ellebaek

SB

,

Graversen

M

,

Detlefsen

S

,

Lundell

L

,

Fristrup

CW

,

Pfeiffer

P

,

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study

.

Clin Exp Metastasis

.

2020

;

37

(

2

):

325

–

32

.

38.

Alyami

M

,

Bonnot

PE

,

Mercier

F

,

Laplace

N

,

Villeneuve

L

,

Passot

G

,

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer

.

Eur J Surg Oncol

.

2021

;

47

(

1

):

123

–

7

.

39.

Sindayigaya

R

,

Dogan

C

,

Demtroder

CR

,

Fischer

B

,

Karam

E

,

Buggisch

JR

,

ASO visual abstract: clinical outcome of patients managed with low-dose cisplatin and doxorubicin delivered as pressurized intraperitoneal aerosol chemotherapy for unresectable peritoneal metastases of gastric cancer

.

Ann Surg Oncol

.

2022

;

29

(

1

):

124

–

5

.

40.

Van de Sande

L

,

Rahimi-Gorji

M

,

Giordano

S

,

Davoli

E

,

Matteo

C

,

Detlefsen

S

,

Electrostatic intraperitoneal aerosol delivery of nanoparticles: proof of concept and preclinical validation

.

Adv Healthc Mater

.

2020

;

9

(

16

):

e2000655

.

https://doi.org/10.1245/s10434-015-4954-9

41.

Khosrawipour

V

,

Khosrawipour

T

,

Diaz-Carballo

D

,

Förster

E

,

Zieren

J

,

Giger-Pabst

U

.

Exploring the spatial drug distribution pattern of pressurized intraperitoneal aerosol chemotherapy (PIPAC)

.

Ann Surg Oncol

.

2016

;

23

(

4

):

1220

–

4

.

.

https://doi.org/10.1515/pp-2017-0006

42.

Schnelle

D

,

Weinreich

FJ

,

Kibat

J

,

Reymond

MA

.

A new ex vivo model for optimizing distribution of therapeutic aerosols: the (inverted) bovine urinary bladder

.

Pleura Peritoneum

.

2017

;

2

(

1

):

37

–

41

.

.

43.

Van de Sande

L

,

Willaert

W

,

Cosyns

S

,

De Clercq

K

,

Shariati

M

,

Remaut

K

,

Establishment of a rat ovarian peritoneal metastasis model to study pressurized intraperitoneal aerosol chemotherapy (PIPAC)

.

BMC Cancer

.

2019

;

19

(

1

):

424

.

44.

Rezniczek

GA

,

Buggisch

J

,

Sobilo

J

,

Launay

A

,

Lerondel

S

,

Le Pape

A

,

Establishment of a mouse ovarian cancer and peritoneal metastasis model to study intraperitoneal chemotherapy

.

Cancers

.

2020

;

12

(

12

):

3818

.

45.

Tan

HL

,

Kim

G

,

Charles

CJ

,

Li

RR

,

Jang

CJ

,

Shabbir

A

,

Safety, pharmacokinetics and tissue penetration of PIPAC paclitaxel in a swine model

.

Eur J Surg Oncol

.

2021

;

47

(

5

):

1124

–

31

.

46.

Mimouni

M

,

Richard

C

,

Adenot

P

,

Letheule

M

,

Tarrade

A

,

Sandra

O

,

Pressurized intra-peritoneal aerosol chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution patterns but leads to deeper penetration depth of doxorubicin in a sheep model

.

BMC Cancer

.

2021

;

21

(

1

):

461

.

47.

Shariati

M

,

Lollo

G

,

Matha

K

,

Descamps

B

,

Vanhove

C

,

Van de Sande

L

,

Synergy between intraperitoneal aerosolization (PIPAC) and cancer nanomedicine: cisplatin-loaded polyarginine-hyaluronic acid nanocarriers efficiently eradicate peritoneal metastasis of advanced human ovarian cancer

.

ACS Appl Mater Interfaces

.

2020

;

12

(

26

):

29024

–

36

.

48.

Castagna

A

,

Zander

AJ

,

Sautkin

I

,

Schneider

M

,

Shegokar

R

,

Konigsrainer

A

,

Enhanced intraperitoneal delivery of charged, aerosolized curcumin nanoparticles by electrostatic precipitation

.

Nanomedicine

.

2021

;

16

(

2

):

109

–

20

.

49.

Rahimi-Gorji

M

,

Van de Sande

L

,

Debbaut

C

,

Ghorbaniasl

G

,

Braet

H

,

Cosyns

S

,

Intraperitoneal aerosolized drug delivery: technology, recent developments, and future outlook

.

Adv Drug Deliv Rev

.

2020

;

160

:

105

–

14

.

50.

Park

SJ

,

Lee

EJ

,

Lee

HS

,

Kim

J

,

Park

S

,

Ham

J

,

Development of rotational intraperitoneal pressurized aerosol chemotherapy to enhance drug delivery into the peritoneum

.

Drug Deliv

.

2021

;

28

(

1

):

1179

–

87

.

51.

Bachmann

C

,

Sautkin

I

,

Nadiradze

G

,

Archid

R

,

Weinreich

FJ

,

Konigsrainer

A

,

Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC)

.

Surg Endosc

.

2021

;

35

(

11

):

6358

–

65

52.

Mikolajczyk

A

,

Khosrawipour

T

,

Kulas

J

,

Migdal

P

,

Arafkas

M

,

Nicpon

J

,

The structural effect of high intensity ultrasound on peritoneal tissue: a potential vehicle for targeting peritoneal metastases

.

BMC Cancer

.

2020

;

20

(

1

):

481

.

53.

Vanmeerbeek

I

,

Sprooten

J

,

De Ruysscher

D

,

Tejpar

S

,

Vandenberghe

P

,

Fucikova

J

,

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology

.

Oncoimmunology

.

2020

;

9

(

1

):

1703449

.

https://doi.org/10.1016/j.pharmthera.2020.107753

54.

Xiao

Y

,

Yu

D

.

Tumor microenvironment as a therapeutic target in cancer

.

Pharmacol Ther

.

2021

;

221

:

107753

.

.